Bispecific antibodies(bsAbs) are a relatively new type of drug in the field of targeted therapeutics. By binding to both CD3 and a tumor-associated antigen, these bsAbs bridge T cells and tumor cells together to initiate tumor cell death, irrespective of T cell receptor specificity, co-stimulation, or peptide antigen presentation. Furthermore, the activation of T cells by CD3 bsAbs stimulates the secretion of a wide variety of cytokines to recruit immune helper cells to further enhance the anti-tumor cell effects.

Current marketed bsAbs that have successfully received market approval

and their listed indication of use

From the concept phase to clinical trials, many companies around the world are accelerating their research and development processes of these drugs, especially CD3-targeting bsAbs. This means that quality control of bsAb drugs becomes even more critical, especially as a novel immunotherapeutic. A key reagent for these quality control studies are recombinant proteins. To support bsAb research and its relevant quality control studies, ACROBiosystems strives to provide high-quality, bioactive, and consistent recombinant proteins including CD3 and many others.

Read Full Texts

We are hiring!

ACROBiosystems is also available at Fisher and VWR!

To receive the latest industry news and updates from ACROBiosystems,

visit our website & follow us on our social media!

Visit our Website

Quality Control